Assessment of Action of Statins in End Stage Renal Disease

  • Majid Malaki Assistant Professor, Department of Pediatric Nephrology, Pediatric Ward Sevome Shaban Hospital , Tehran, IRAN
Keywords: Chronic kidney disease, Atorvastatin, End stage renal disease, Cardiovascular disease, Lipid profile


Background and Aim: Chronic kidney disease (CKD) is one among the highest cause of morbidity globally. Statins are the top list of drugs used for them. It has been shown that the action of statins in severe CKD is paradoxical because lipid management cannot increase their survival. Methods: Sixteen CKD patients on dialysis for not less than 6 months who were receiving low dose of atorvastatin were recruited into the study. Blood investigations were performed and their results were compared with another group of non-user of lipid lowering agents. Results: Lipid profile, uric acid, calcium, phosphorous, parathyroid hormone, Vitamin D increased but these changes were significant in uric acid and Vitamin D level in the dialysis patients who receive low dose atorvastatin when compared to nonusers of atorvastatin. Conclusion: Our results showed that atorvastatin in low dose can increase serum vitamin D and serum uric acid in ESRD patients. This side effect can be the herald of accelerated cardiovascular disease and metabolic bone disease. In contrary to popular belief, statins effect on CKD patients is deleterious by increase serum uric acid in an unknown mechanism.

Table 1: Comparison of laboratory tests between statin users and non-users
How to Cite
Malaki, M. (2021). Assessment of Action of Statins in End Stage Renal Disease. International Journal of Clinical and Experimental Physiology, 7(4), 143-145.